Insider share buying can't stop the Starpharma share price sliding again today

The Starpharma Ltd (ASX:SPL) share price is falling again today after a shock FDA rejection.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Ltd (ASX: SPL) share price is 9% lower today to change hands for just 90 cents after a near on 30% collapse yesterday on the back of news that the US regulator the FDA rejected its application to approve its VivaGel BV product for sale in the U.S.

However, in some good news for shareholders it's been revealed that yesterday a Starpharma director and insider, Robert Thomas, bought 50,000 shares for $47,000 on market at 96 cents per share.

This suggests Mr. Thomas at least has faith the biotech will eventually get its VivaGel BV product approved in the U.S., although the pathway ahead now is unclear as Starpharma has admitted the FDA requires "more clinical data" prior to approval.

It appears investors are taking a sell first, ask questions later approach though as management's credibility has been hurt by the FDA rejection as many in the market believed Starpharma had the clinical data already to secure approval.

The uncertainty over the situation now is likely to keep a lid in the share price until management provides a further update or proper roadmap to approval.

Starpharma does have plenty of potential on paper at least via its drug delivery technology and products already in market and is well funded with $49.5 million cash on hand. However, whether it can translate this potential into profits remains to be seen as investors are largely reliant on the worth of management's guidance on the science as to the company's potential.

For example many biotechs in the research and development space often just end up destroying investor capital such as Admedus Ltd (ASX: AHZ), Prana Biotechnolgy Ltd (ASX: PBT), Mesoblast limited (ASX: MSB) and Acrux Limited (ASX: ACR).

In fact as far as I can remember Sirtex Medical is the only start-up type biotech or healthcare business to list and go on to become a roaring success by posting big profits for investors. So there can be exceptions to the rule, but they are unusual.

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Beach Energy, Myer, Pexa, and Pinnacle shares are falling today

These shares are under pressure on Thursday. What's going?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Block, Canyon, Fisher & Paykel Healthcare, and Mesoblast shares are falling today

These shares are having a tough time on hump day. What's going on?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Fisher & Paykel Healthcare, Magellan, Resolute Mining, and Westgold shares are sinking today

These shares are starting the week deep in the red. But why?

Read more »

plummeting gold share price
Gold

Guess which ASX 200 gold stock just plunged 12% on FY 2025 production woes

The ASX 200 gold stock is taking a sharp fall on Monday. Let’s find out why.

Read more »

Man with a hand on his head looks at a red stock market chart showing a falling share price.
Share Fallers

These were the worst performing ASX 200 shares in January 2025

These shares had a month to forget. Why were investors selling them? Let's find out.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Magellan, Medadvisor, Origin Energy, and Pointsbet shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
Share Fallers

Why Appen, Credit Corp, Mineral Resources, and Zip shares are sinking today

These shares are missing out on the good times on Thursday and dropping into the red.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Accent, Aroa, Playside, and Premier Investments shares are tumbling today

These shares are having a tough time on hump day. But why?

Read more »